(Q35166825)

6 August 2017

1 reference

title

Rethinking clinical trials for cytostatic drugs (English)

1 reference

6 August 2017

Andrew W Millar

1

1 reference

PubMed ID

12835674

6 August 2017

Kevin P Lynch

series ordinal

2

1 reference

PubMed ID

12835674

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

6 August 2017

Nature Reviews Cancer

1 reference

6 August 2017

3

1 reference

6 August 2017

540-545

1 reference

6 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc1124

6 August 2017

0 references

cites work

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

21 January 2018

1 reference

ErbB2 pathways in heart and neural diseases

21 January 2018

1 reference

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

21 January 2018

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

21 January 2018

1 reference

Influence of unrecognized molecular heterogeneity on randomized clinical trials

21 January 2018

1 reference

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

End points and United States Food and Drug Administration approval of oncology drugs

21 January 2018

1 reference

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials

21 January 2018

1 reference

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

21 January 2018

1 reference

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

31 March 2020

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

31 March 2020

1 reference

Randomized discontinuation design: application to cytostatic antineoplastic agents

31 March 2020

1 reference

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1124

1 reference

6 August 2017

1 reference

PubMed ID

12835674